Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy

Virus Genes

Volumn 47, Issue 1, 2013, Pages 1-9

  Deng, Xiao Lin ^a   Li, Qing Ling ^a   Guo, Jin Jun ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Antiviral therapy; Drug resistance; Entecavir; Hepatitis B virus; Lamivudine; Quasispecies evolution

Indexed keywords

ENTECAVIR; ISOLEUCINE; LAMIVUDINE; LEUCINE; METHIONINE; RNA DIRECTED DNA POLYMERASE; VALINE; VIRUS DNA;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA BLOOD LEVEL; DNA DETERMINATION; DNA SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS MUTANT; VIRUS MUTATION; VIRUS STRAIN; WILD TYPE;

HEPATITIS B VIRUS;

EID: 84876399755     PISSN: 09208569     EISSN: 1572994X     Source Type: Journal    
DOI: 10.1007/s11262-013-0915-1     Document Type: Article

References (28)

1. A.H. Malik, W.M. Lee, Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann. Intern. Med. 132, 723-731 (2000)
2. C.L. Lai, R.N. Chien, N.W. Leung, T.T. Chang, R. Guan, D.I. Tai et al., A one year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339, 61-68 (1998)
3. J.L. Dienstag, E.R. Schiff, T.L. Wright, R.P. Perrillo, H.W. Hann, Z. Goodman et al., Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341, 1256-1263 (1999)
4. Y.F. Liaw, J.J. Sung, W.C. Chow, G. Farrell, C.Z. Lee, H. Yuen et al., Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351, 1521-1531 (2004)
5. G.V. Papatheodoridis, E. Dimou, K. Dimakopoulos, S. Manolakopoulos, I. Rapti, G. Kitis et al., Outcome of hepatitis Be antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 42, 121-129 (2005)
6. C.L. Lai, J. Dienstag, E. Schiff, N.W. Leung, M. Atkins, C. Hunt et al., Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36, 687-696 (2003)
7. H.J. Kim, J.H. Park, D.I. Park, Y.K. Cho, C.I. Sohn, W.K. Jeon et al., Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J. Gastroenterol. Hepatol. 25, 1374-1380 (2010)
8. O. Lada, Y. Benhamou, A. Cahour, C. Katlama, T. Poynard, V. Thibault, In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 9, 353-363 (2004)
9. F. van Bömmel, T. Wünsche, S. Mauss, P. Reinke, A. Bergk, D. Schürmann, B. Wiedenmann, T. Berg, Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40, 1421-1425 (2004)
10. M. Sherman, C. Yurdaydin, H. Simsek et al., Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 48, 99-108 (2008)
11. S. Levine, D. Hernandez, G. Yamanaka, S. Zhang, R. Rose, S. Weinheimer et al., Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob. Agents Chemother. 46, 2525-2532 (2002)
12. R.J. Colonno, R. Rose, C.J. Baldick, S. Levine, K. Pokornowski, C.F. Yu et al., Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44, 1656-1665 (2006)
13. D.J. Tenney, R.E. Rose, C.J. Baldick, S.M. Levine, K.A. Pokornowski, A.W. Walsh et al., Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother. 51, 902-911 (2007)
14. S. Ijaz, C. Arnold, S. Dervisevic, J. Mechurova, N. Tatman, R.S. Tedder, N.V. Naoumov, Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. J. Med. Virol. 80, 1160-1170 (2008)
15. J.J. Guo, Q.L. Li, X.F. Shi, D.Z. Zhang, A.Z. Zeng, T. Feng et al., Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/ nucleotide-naïve patient. Antiviral Res. 81, 180-183 (2009)
16. A. Snow-Lampart, B. Chappell, M. Curtis, Y. Zhu, F. Myrick, J. Schawalder et al., No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 53, 763-773 (2011)
17. K.P. Fischer, K.S. Gutfreund, D.L. Tyrrell, Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug Resist Updat 4, 118-128 (2001)
18. F. van Bömmel, B. Zöllner, C. Sarrazin, U. Spengler, D. Hüppe, B. Möller et al., Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 44, 318-325 (2006)
19. P. Zhao, C. Wang, L. Huang, D. Xu, T. Li, Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B. Antiviral Res. 96, 100-104 (2012)
20. S.Y. Ko, W.H. Choe, S.Y. Kwon, J.H. Kim, J.W. Seo, K.H. Kim et al., Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy. Scand. J. Gastroenterol. 47, 1362-1367 (2012)
21. A. Ono, F. Suzuki, Y. Kawamura, H. Sezaki, T. Hosaka, N. Akuta et al., Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J. Hepatol. 57, 508-514 (2012)
22. D.J. Tenney, S.M. Levine, R.E. Rose, A.W. Walsh, S.P. Weinheimer, L. Discotto, M. Plym et al., Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob. Agents Chemother. 48, 3498-3507 (2004)
23. H.J. Yuan, W.M. Lee, Molecular mechanisms of resistance to antiviral therapy in patients with chronic hepatitis B. Curr. Mol. Med. 7, 185-197 (2007)
24. S. Villet, A. Ollivet, C. Pichoud, L. Barraud, J.P. Villeneuve, C. Trepo et al., Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J. Hepatol. 46, 531-538 (2007)
25. F. Zoulim, Hepatitis B virus resistance to entecavir in nucleoside naive patients: does it exist? Hepatology 44, 1404-1407 (2006)
26. H.J. Yim, M. Hussain, Y. Liu, S.N. Wong, S.K. Fung, A.S. Lok, Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44, 703-712 (2006)
27. J.P. Villeneuve, D. Durantel, S. Durantel, C. Westland, S. Xiong, C.L. Brosgart et al., Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J. Hepatol. 39, 1085-1089 (2003)
28. F. Liu, L. Chen, D.M. Yu, L. Deng, R. Chen, Y. Jiang et al., Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy. Gut 60, 1269-1277 (2011)